Dots

News

First patient at Virginia Commonwealth University (VCU) Medical Center implanted in EndoStim’s LESS GERD clinical trial for gastroesophageal reflux disease (GERD)

RICHMOND and DALLAS, JANUARY 24, 2017 – Virginia Commonwealth University (VCU) Medical Center and EndoStim, Inc., announced that the first patient in Richmond, Virginia has been implanted with the EndoStim device in the Lower Esophageal Sphincter Stimulation for GERD (LESS…

read more

First two patients at HonorHealth Research Institute implanted in EndoStim's LESS GERD clinical trial for gastroesophageal reflux disease (GERD)

SCOTTSDALE, Ariz. and DALLAS, Dec. 20, 2016 /PRNewswire/ -- HonorHealth Research Institute and EndoStim, Inc., announced that the first two patients in Scottsdale, AZ have been implanted with the EndoStim device in the Lower Esophageal Sphincter Stimulation for GERD (LESS…

read more

First two patients at SurgOne Foregut Institute implanted in EndoStim's LESS GERD clinical trial for gastroesophageal reflux disease (GERD)

ENGLEWOOD, Colo. and DALLAS, Dec. 1, 2016 /PRNewswire/ -- SurgOne Foregut Institute and EndoStim, Inc., announced that the first two patients in Englewood, CO have been implanted with the EndoStim device in the Lower Esophageal Sphincter Stimulation for GERD (LESS GERD)…

read more

EndoStim Opens its New Corporate Headquarters in Dallas

EndoStim Inc. is pleased to announce the opening of its new corporate headquarters in Dallas, Texas. EndoStim’s research and development will continue to operate from its Austin, Texas, office and EndoStim BV’s international headquarters will remain in Nijmegen, The Netherlands.…

read more

First patient implanted in EndoStim's Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) clinical trial

LOS ANGELES and ST. LOUIS, Nov. 3, 2016 /PRNewswire/ -- EndoStim, Inc., announced that the first patient has been implanted with the EndoStim device in the LESS GERD trial, at the University of Southern California. The results from the trial…

read more

New data on EndoStim® therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at United European Gastroenterology Week 2016

ST. LOUIS and NIJMEGEN, The Netherlands – EndoStim, Inc., a medical device company, announced new data presented on its neurostimulation therapy for gastroesophageal reflux disease (GERD) at the 2016 United European Gastroenterology (UEG) annual meeting in Vienna, Austria. The presentations…

read more

Endostim featured in the news on NDR Aktuell in Germany

https://youtu.be/UocaFo5hWx0

read more

New data on EndoStim therapy for the treatment of gastro-esophageal reflux disease (GERD) presented at Digestive Disease Week® 2016

PR NEWSWIRE ST. LOUIS and NIJMEGEN, The Netherlands, May 31, 2016 - EndoStim, Inc., a medical device company, today announced new data were presented on its new neurostimulation therapy for gastroesophageal reflux disease (GERD) at the 2016 Digestive Disease Week…

read more

EndoStim Names Rohan Hoare, Ph.D., as New President and CEO

PR NEWSWIRE ST. LOUIS, MO and NIJMEGEN, The Netherlands, May 17, 2016 /PR Newswire/ - EndoStim, Inc., a medical device company that has developed neurostimulation therapy for gastroesophageal reflux disease (GERD), today announced the appointment of Rohan Hoare, Ph.D., as…

read more

EndoStim Secures $25 Million in Funding to Expand Commercialization Efforts and Conduct a Pivotal U.S. Clinical Trial

PR NEWSWIRE NIJMEGEN, The Netherlands and ST. LOUIS, MO, May 12, 2016 /PR Newswire/ - EndoStim, Inc., a medical device company that has developed neurostimulation therapy for gastroesophageal reflux disease (GERD), today announced it has completed a Series D financing…

read more

EndoStim's Neurostimulation Therapy for Gastroesophageal Reflux Disease Approved in Brazil

PR NEWSWIRE NIJMEGEN, Netherlands and ST. LOUIS, Dec. 2, 2015 /PRNewswire/ -- EndoStim is pleased to announce approval of its minimally-invasive therapy for gastroesophageal reflux disease (GERD) in Brazil. EndoStim received approval from ANVISA, the Brazilian health authority, for its…

read more

Two year outcomes of EndoStim therapy presented at UEG Week in Berlin, Germany

Dr. Leonardo Rodriguez presented the 2 year outcomes of a single center long-term trial of EndoStim therapy for severe GERD. The featured study included 24 patients in Santiago, Chile; after 24 months of continuous EndoStim therapy, patients available for follow-up…

read more

EndoStim receives CE Mark for full body MRI use with EndoStim II LES Stimulation System

PR NEWSWIRE NIJMEGEN, Netherlands, Oct. 20, 2015 /PRNewswire/ -- EndoStim, a medical device company that has developed neurostimulation therapy for gastroesophageal reflux disease (GERD), announced CE Mark approval for a significant expansion of options for Magnetic Resonance Imaging (MRI) use…

read more

EndoStim's neurostimulation therapy for GERD receives permanent reimbursement coverage in Germany

PR NEWSWIRE NIJMEGEN, the Netherlands, October 13, 2015 - EndoStim, a medical device company developing neurostimulation therapy for gastroesophageal reflux disease (GERD), announced today that InEK, the German Institute for the Hospital Remuneration System, has decided to approve the request…

read more

International Multicenter Trial results of EndoStim LES Stimulation therapy confirm safety and efficacy in patients with GERD

PR NEWSWIRE ST. LOUIS and NIJMEGEN, the Netherlands, July 17, 2015 /PRNewswire/ -- EndoStim announced publication of interim results of an international multicenter trial demonstrating safety and efficacy of its minimally-invasive therapy in patients with GERD insufficiently controlled by medication…

read more

EndoStim Launches Second Generation Neurostimulation Device for GERD

PR NEWSWIRE NIJMEGEN, Netherlands and ST. LOUIS, May 18, 2015 /PRNewswire/ -- EndoStim announces CE Mark approval and the European launch of the EndoStim II, its second generation LES Stimulation System to treat gastroesophageal reflux disease (GERD). The EndoStim II…

read more

Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville

PR NEWSWIRE St Louis, MO and Nijmegen, the Netherlands – May 5, 2015 EndoStim, a medical device company developing lower esophageal sphincter (LES) stimulation therapy for gastroesophageal reflux disease (GERD) announced long-term, 3-year, positive safety and efficacy results. The results…

read more

EndoStim Therapy for Gastroesophageal Reflux Disease Launched in Mexico

PR NEWSWIRE NIJMEGEN, Netherlands and ST. LOUIS, May 4, 2015 /PRNewswire/ -- EndoStim is pleased to launch its minimally-invasive therapy for gastroesophageal reflux disease (GERD) in Mexico, in collaboration with Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran" (INCMNSZ)…

read more

EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients

PR NEWSWIRE ST LOUIS and the HAGUE, Netherlands, March 25, 2015 /PRNewswire/ -- EndoStim announced publication of two-year results of LES Stimulation therapy for chronic gastro-esophageal reflux disease (GERD) in the March issue of the journal Surgery [Surgery. 2015; 157(3):556-567],…

read more

EndoStim therapy for reflux receives positive reimbursement decision for 65 hospitals throughout Germany

PR NEWSWIRE EndoStim announced today the renewal of a positive reimbursement decision in Germany, NUB Status 1, for its lower esophageal sphincter (LES) stimulation system, a minimally-invasive neurostimulation treatment for gastroesophageal reflux disease (GERD). InEK, the German institute for the…

read more

EndoStim announces expansion of German reimbursement for EndoStim® LES Stimulation Therapy for GERD

PR Newswire Clinics throughout Germany receive NUB approval for 2014 THE HAGUE, NETHERLANDS and ST. LOUIS, MO, February 13, 2014/ -- EndoStim announced today that 40 hospitals in Germany have received NUB (Neue Untersuchungsund Behandlungsmethoden) approval for its EndoStim® LES…

read more

Dr. H.G. Schulz showcases live EndoStim procedures at Dusseldorf Hernia Symposium and Endoclub Nord

Dr. H.G. Schulz, Chief of Surgery at Evangelisches Krankenhaus Castrop-Rauxel, demonstrated how the EndoStim System is placed in live procedure broadcasts at the Dusseldorf Hernia Symposium in September and at the 21st Endoclub Nord in Hamburg earlier this month.

read more

International Multi-Center trial update presented at ACG

Dr. Edy Soffer, Professor of Medicine, Director of GI Motility at the University of Southern California Keck School of Medicine, presented the interim 6-month results of an international multi-center trial of EndoStim therapy to treat GERD. The ongoing study includes…

read more

EndoStim treats first patient with severe acid reflux in Germany with EndoStim LES Stimulation System

PR Newswire THE HAGUE, Netherlands and ST. LOUIS, Feb. 19, 2013 /PRNewswire/ -- The first patient in Germany has received treatment with EndoStim's LES Stimulation Therapy for acid reflux or gastroesophageal reflux disease (GERD). The procedure was successfully performed by…

read more

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close